Delaware
|
68-0328265
|
(State of incorporation)
|
(I.R.S. Employer Identification Number)
|
Large accelerated filer o
|
|
|
|
Accelerated filer þ
|
Non-accelerated filer o
|
|
(Do not check if a smaller reporting company)
|
|
Smaller reporting company o
|
|
|
|
|
Emerging growth company o
|
Title of Each Class of Securities to be
Registered |
Amount to be Registered(1)
|
Proposed Maximum Offering
Price Per Share |
Proposed Maximum
Aggregate Offering Price |
Amount of Registration Fee
|
Common Stock, par value $0.001 per share
|
|
|
|
|
Shares issued on July 3, 2019 under the 2017 Plan
|
42,614(2)
|
$7.53(7)
|
$320,883.42
|
$41.65
|
Shares remaining to be issued under the 2017 Plan
|
457,386(3)
|
$3.09(8)
|
$1,413,322.74
|
$183.45
|
Shares issued on August 5, 2019 under the 2015 Plan
|
1,930,841(4)
|
$6.67(9)
|
$12,878,709.47
|
$1,671.66
|
Shares remaining to be issued under the 2015 Plan
|
569,159(5)
|
$3.09(8)
|
$1,758,701.31
|
$228.28
|
Shares to be issued under the ESPP
|
500,127(6)
|
$3.09(8)
|
$1,545,392.43
|
$200.59
|
Total
|
3,500,127
|
|
$17,917,009.37
|
$2,325.63
|
(1)
|
Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional shares of the registrant’s Common Stock, par value $0.001 per share (“Common Stock”), that become issuable under the Endologix, Inc. Amended and Restated 2015 Stock Incentive Plan (the “2015 Plan”), the Endologix, Inc. 2017 Inducement Stock Incentive Plan, as amended (the “2017 Plan”), or the Endologix, Inc. Amended and Restated 2006 Employee Stock Purchase Plan (the “ESPP”) by reason of any stock dividend, stock split, recapitalization or any similar transaction effected without the receipt of consideration that results in an increase in the number of the outstanding shares of Common Stock.
|
(2)
|
Represents 42,614 shares of Common Stock reserved for issuance pursuant to equity unit awards issued on July 3, 2019 following approval by the compensation committee of the Board of Directors of Endologix, Inc. (the “Compensation Committee”) of an increase in the number of shares of Common Stock reserved under the 2017 Plan.
|
(3)
|
Represents 500,000 additional shares of Common Stock reserved for issuance pursuant to the 2017 Plan minus the shares reserved for issuance pursuant to the equity awards referenced in footnote 2.
|
(4)
|
Represents 1,930,841 shares of Common Stock reserved for issuance pursuant to equity awards issued on August 5, 2019 following stockholder approval of an increase in the number of shares of Common Stock reserved under the 2015 Plan.
|
(5)
|
Represents 2,500,000 additional shares of Common Stock reserved for issuance pursuant to the 2015 Plan minus the shares reserved for issuance pursuant to the equity awards referenced in footnote 4.
|
(6)
|
Represents 500,127 additional shares of Common Stock reserved for issuance under the ESPP.
|
(7)
|
Calculated pursuant to Rule 457(h) of the Securities Act on the basis of $7.53 per share, which represents the exercise price of the stock option awards granted on July 3, 2019, as described in footnote 2.
|
(8)
|
Estimated pursuant to Rule 457(c) and Rule 457(h) of the Securities Act, solely for purpose of calculating the registration fee, which is the average of the high and low sales price of the Common Stock as reported on the NASDAQ Global Select Market on October 28, 2019. With respect to the ESPP only, the amount is multiplied by 85%, which is the percentage of the trading price per share applicable to purchasers under the ESPP.
|
(9)
|
Calculated pursuant to Rule 457(h) of the Securities Act on the basis of $6.67 per share, which represents the exercise price of the equity awards granted on August 5, 2019, as described in footnote 4.
|
•
|
the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018, filed with the Commission on April 1, 2019, as amended by Amendment No. 1 to Form 10-K, filed with the Commission on April 30, 2019 (the “Annual Report”);
|
•
|
the Registrant’s Definitive Proxy Statement on Schedule 14A, filed with the Commission on July 8, 2019;
|
•
|
all other reports filed by the Registrant pursuant to Section 13(a) or 15(d) of the Exchange Act since the end of the fiscal year covered by the Annual Report; and
|
•
|
the description of the Common Stock contained in the Registrant’s registration statement on Form 8-A, filed with the Commission on June 18, 1996, including any amendment or report filed for the purpose of updating such description.
|
Signature
|
|
Title
|
|
Date
|
|
|
|
||
/s/ John Onopchenko
|
|
Chief Executive Officer and Director
|
|
October 31, 2019
|
(John Onopchenko)
|
|
(Principal Executive Officer)
|
|
|
|
|
|
||
/s/ Vaseem Mahboob
|
|
Chief Financial Officer
|
|
October 31, 2019
|
(Vaseem Mahboob )
|
|
(Principal Financial and Accounting Officer)
|
|
|
|
|
|
||
/s/ Daniel Lemaitre
|
|
Chairman of the Board
|
|
October 31, 2019
|
(Dan Lemaitre)
|
|
|
|
|
|
|
|
||
/s/ Thomas F. Zenty, III
|
|
Director
|
|
October 31, 2019
|
(Thomas F. Zenty III)
|
|
|
|
|
|
|
|
||
/s/ Thomas C. Wilder
|
|
Director
|
|
October 31, 2019
|
(Thomas C. Wilder)
|
|
|
|
|
|
|
|
||
/s/ Gregory D. Waller
|
|
Director
|
|
October 31, 2019
|
(Gregory D. Waller)
|
|
|
|
|
|
|
|
||
/s/ Leslie V. Norwalk
|
|
Director
|
|
October 31, 2019
|
(Leslie V. Norwalk)
|
|
|
|
|
Exhibit Number
|
|
Exhibit
|
|
Amended and Restated Certificate of Incorporation (as updated through March 5, 2019 and currently in effect) (incorporated by reference to Exhibit 3.1 to the Registrant’s Annual Report on Form 10-K, filed with the Commission on April 1, 2019).
|
|
|
Amended and Restated Bylaws (as updated through June 14, 2018 and currently in effect) (incorporated by reference to Exhibit 3.2 to the Registrant’s Annual Report on Form 10-K, filed with the Commission on April 1, 2019).
|
|
|
Specimen Certificate of Common Stock (incorporated by reference to Exhibit 4.1 to Amendment No. 2 to the Registrant’s Registration Statement on Form S-1 (Filing No. 333-04560), filed with the Commission on June 10, 1996).
|
|
|
Updated Specimen Certificate of Common Stock effective as of May 22, 2014 (incorporated by reference to Exhibit 4.1.1 to the Registrant’s Annual Report on Form 10-K, filed with the Commission on March 2, 2015).
|
|
|
Endologix, Inc. Amended and Restated 2015 Stock Incentive Plan (incorporated by reference to Appendix A to the Registrant’s Definitive Proxy Statement on Schedule 14A, filed with the Commission on July 8, 2019).
|
|
|
Endologix, Inc. 2017 Inducement Stock Incentive Plan, as amended (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, File No. 000-28440, filed on October 30, 2017).
|
|
|
Amendment to Endologix, Inc. 2017 Inducement Stock Incentive Plan +
|
|
|
Opinion of Stradling Yocca Carlson & Rauth, P.C. +
|
|
|
Consent of Independent Registered Public Accounting Firm. +
|
|
|
Consent of Stradling Yocca Carlson & Rauth, P.C. (contained in Exhibit 5.1). +
|
|
|
Power of Attorney (included on the signature page to this Registration Statement). +
|
|
STRADLING YOCCA CARLSON & RAUTH, P.C.
660 NEWPORT CENTER DRIVE, SUITE 1600
NEWPORT BEACH, CA 92660-6422
SYCR.COM
|
CALIFORNIA
NEWPORT BEACH
SACRAMENTO
SAN DIEGO
SAN FRANCISCO
SANTA BARBARA
SANTA MONICA
COLORADO
DENVER
NEVADA
RENO
WASHINGTON
SEATTLE
|